Watch Demo

Neurodiagnostics Market Research Report by Product, Indication, End User, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Neurodiagnostics Market Research Report by Product, Indication, End User, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:138

  • Report ID:6402237

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Neurodiagnostics Market Research Report by Product (Clinical Testing Instrument, Diagnostic & Imaging System, and Reagent & Consumable), Indication, End User, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

The United States Neurodiagnostics Market size was estimated at USD 1,446.89 million in 2022 and expected to reach USD 1,609.18 million in 2023, projecting growth at a CAGR of 9.35% to reach USD 2,958.59 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Neurodiagnostics Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Neurodiagnostics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Neurodiagnostics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Neurodiagnostics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Neurodiagnostics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market is studied across Clinical Testing Instrument, Diagnostic & Imaging System, and Reagent & Consumable. The Clinical Testing Instrument is further studied across NGS Instrument, PCR Instrument, and Sanger Sequencer. The Diagnostic & Imaging System is further studied across Angiography System, CT Scanner, EEG System, EMG Device, MEG Device, MRI System, PET Scanner, and Ultrasound Imaging System. The Reagent & Consumable is further studied across Antibody, Buffer, Enzyme, Protein, & Peptide, Media & Sera, Probe, and Solvent.

Based on Indication, the market is studied across Epilepsy, Headache Disorder, Neurodegenerative Diseases, Sleep Disorder, and Stroke.

Based on End User, the market is studied across Diagnostic Laboratory & Imaging Center, Hospital & Clinic, Ambulatory Care Center, and Neurology Center.

Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Neurodiagnostics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Neurodiagnostics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Neurodiagnostics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Neurodiagnostics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Neurodiagnostics Market, including Abbott Laboratories Inc., Adeor Medical AG, Advanced Brain Monitoring, Inc., Canon Medical Systems USA, Inc., DEYMED Diagnostic s.r.o., F. Hoffmann-La Roche Ltd., GE Healthcare, Koninklijke Philips N.V., Lifelines Neuro Company, LLC, Medtronic PLC, Mitsar Co., Ltd., Natus Medical Incorporated, Nihon Kohden Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Neurodiagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Neurodiagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Neurodiagnostics Market?
4. What is the competitive strategic window for opportunities in the United States Neurodiagnostics Market?
5. What are the technology trends and regulatory frameworks in the United States Neurodiagnostics Market?
6. What is the market share of the leading vendors in the United States Neurodiagnostics Market?
7. What modes and strategic moves are considered suitable for entering the United States Neurodiagnostics Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing burden of neurological disorders in the U.S.
5.1.1.2. Rapid adoption of early detection and prevention method
5.1.2. Restraints
5.1.2.1. Associated high cost of neurodiagnostics
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in genomics and proteomics for neurodegenerative disorders diagnosis
5.1.4. Challenges
5.1.4.1. Shortage of neurosurgeons and neurologists in the U.S.
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Neurodiagnostics Market, by Product
6.1. Introduction
6.2. Clinical Testing Instrument
6.3.1. NGS Instrument
6.3.2. PCR Instrument
6.3.3. Sanger Sequencer
6.3. Diagnostic & Imaging System
6.4.1. Angiography System
6.4.2. CT Scanner
6.4.3. EEG System
6.4.4. EMG Device
6.4.5. MEG Device
6.4.6. MRI System
6.4.7. PET Scanner
6.4.8. Ultrasound Imaging System
6.4. Reagent & Consumable
6.5.1. Antibody
6.5.2. Buffer
6.5.3. Enzyme, Protein, & Peptide
6.5.4. Media & Sera
6.5.5. Probe
6.5.6. Solvent

7. Neurodiagnostics Market, by Indication
7.1. Introduction
7.2. Epilepsy
7.3. Headache Disorder
7.4. Neurodegenerative Diseases
7.5. Sleep Disorder
7.6. Stroke

8. Neurodiagnostics Market, by End User
8.1. Introduction
8.2. Diagnostic Laboratory & Imaging Center
8.3. Hospital & Clinic
8.4. Ambulatory Care Center
8.5. Neurology Center

9. California Neurodiagnostics Market
9.1. Introduction

10. Florida Neurodiagnostics Market
10.1. Introduction

11. Illinois Neurodiagnostics Market
11.1. Introduction

12. New York Neurodiagnostics Market
12.1. Introduction

13. Ohio Neurodiagnostics Market
13.1. Introduction

14. Pennsylvania Neurodiagnostics Market
14.1. Introduction

15. Texas Neurodiagnostics Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Product Portfolio Analysis, By Key Player
16.5. Competitive Scenario
16.5.1. Merger & Acquisition
16.5.2. Agreement, Collaboration, & Partnership
16.5.3. New Product Launch & Enhancement
16.5.4. Investment & Funding
16.5.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Abbott Laboratories Inc.
17.2. Adeor Medical AG
17.3. Advanced Brain Monitoring, Inc.
17.4. Canon Medical Systems USA, Inc.
17.5. DEYMED Diagnostic s.r.o.
17.6. F. Hoffmann-La Roche Ltd.
17.7. GE Healthcare
17.8. Koninklijke Philips N.V.
17.9. Lifelines Neuro Company, LLC
17.10. Medtronic PLC
17.11. Mitsar Co., Ltd.
17.12. Natus Medical Incorporated
17.13. Nihon Kohden Corporation
17.14. Siemens Healthineers AG
17.15. Thermo Fisher Scientific, Inc.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES NEURODIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES NEURODIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES NEURODIAGNOSTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES NEURODIAGNOSTICS MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES NEURODIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
FIGURE 12. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENT, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENT, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCER, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
FIGURE 17. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ANGIOGRAPHY SYSTEM, 2018-2030 (USD MILLION)
FIGURE 18. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CT SCANNER, 2018-2030 (USD MILLION)
FIGURE 19. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EEG SYSTEM, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EMG DEVICE, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MEG DEVICE, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MRI SYSTEM, 2018-2030 (USD MILLION)
FIGURE 23. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PET SCANNER, 2018-2030 (USD MILLION)
FIGURE 24. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING SYSTEM, 2018-2030 (USD MILLION)
FIGURE 25. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
FIGURE 26. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ANTIBODY, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY BUFFER, 2018-2030 (USD MILLION)
FIGURE 28. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ENZYME, PROTEIN, & PEPTIDE, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MEDIA & SERA, 2018-2030 (USD MILLION)
FIGURE 30. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PROBE, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SOLVENT, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 33. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 34. UNITED STATES NEURODIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 35. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
FIGURE 36. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY HEADACHE DISORDER, 2018-2030 (USD MILLION)
FIGURE 37. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
FIGURE 38. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SLEEP DISORDER, 2018-2030 (USD MILLION)
FIGURE 39. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
FIGURE 40. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 41. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 42. UNITED STATES NEURODIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY END USER, 2030
FIGURE 43. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORY & IMAGING CENTER, 2018-2030 (USD MILLION)
FIGURE 44. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINIC, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTER, 2018-2030 (USD MILLION)
FIGURE 46. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CENTER, 2018-2030 (USD MILLION)
FIGURE 47. CALIFORNIA NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. FLORIDA NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. ILLINOIS NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. NEW YORK NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. OHIO NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. PENNSYLVANIA NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. TEXAS NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. UNITED STATES NEURODIAGNOSTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 55. UNITED STATES NEURODIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 56. UNITED STATES NEURODIAGNOSTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. UNITED STATES NEURODIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENT, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENT, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENT, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENT, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCER, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCER, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, BY STATE, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ANGIOGRAPHY SYSTEM, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ANGIOGRAPHY SYSTEM, BY STATE, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CT SCANNER, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CT SCANNER, BY STATE, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EEG SYSTEM, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EEG SYSTEM, BY STATE, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EMG DEVICE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EMG DEVICE, BY STATE, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MEG DEVICE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MEG DEVICE, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MRI SYSTEM, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MRI SYSTEM, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PET SCANNER, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PET SCANNER, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING SYSTEM, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING SYSTEM, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ANTIBODY, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ANTIBODY, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY BUFFER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY BUFFER, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ENZYME, PROTEIN, & PEPTIDE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ENZYME, PROTEIN, & PEPTIDE, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MEDIA & SERA, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY MEDIA & SERA, BY STATE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PROBE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PROBE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SOLVENT, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SOLVENT, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY HEADACHE DISORDER, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY HEADACHE DISORDER, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SLEEP DISORDER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY SLEEP DISORDER, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STROKE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORY & IMAGING CENTER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORY & IMAGING CENTER, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINIC, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINIC, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTER, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CENTER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CENTER, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CALIFORNIA NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 67. CALIFORNIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. CALIFORNIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. CALIFORNIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. FLORIDA NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 71. FLORIDA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. FLORIDA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. FLORIDA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ILLINOIS NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. ILLINOIS NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. ILLINOIS NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. ILLINOIS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. NEW YORK NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 79. NEW YORK NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. NEW YORK NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. NEW YORK NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. OHIO NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 83. OHIO NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. OHIO NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. OHIO NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. PENNSYLVANIA NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 87. PENNSYLVANIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. PENNSYLVANIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. PENNSYLVANIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. TEXAS NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 91. TEXAS NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. TEXAS NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. TEXAS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES NEURODIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 95. UNITED STATES NEURODIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 96. UNITED STATES NEURODIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 97. UNITED STATES NEURODIAGNOSTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 98. UNITED STATES NEURODIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 99. UNITED STATES NEURODIAGNOSTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 100. UNITED STATES NEURODIAGNOSTICS MARKET MERGER & ACQUISITION
TABLE 101. UNITED STATES NEURODIAGNOSTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 102. UNITED STATES NEURODIAGNOSTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 103. UNITED STATES NEURODIAGNOSTICS MARKET INVESTMENT & FUNDING
TABLE 104. UNITED STATES NEURODIAGNOSTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 105. UNITED STATES NEURODIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories Inc.
Adeor Medical AG
Advanced Brain Monitoring, Inc.
Canon Medical Systems USA, Inc.
DEYMED Diagnostic s.r.o.
F. Hoffmann-La Roche Ltd.
GE Healthcare
Koninklijke Philips N.V.
Lifelines Neuro Company, LLC
Medtronic PLC
Mitsar Co., Ltd.
Natus Medical Incorporated
Nihon Kohden Corporation
Siemens Healthineers AG
Thermo Fisher Scientific, Inc.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.